|
|
Prepublished online as a Blood First Edition Paper on May 15, 2003; DOI 10.1182/blood-2002-09-2763.
 Previous Article | Table of Contents | Next Article 
Blood, 15 September 2003, Vol. 102, No. 6, pp. 2205-2212
NEOPLASIA
Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions
Brian J. P. Huntly,
Francois Guilhot,
Alistair G. Reid,
George Vassiliou,
Evelin Hennig,
Christina Franke,
Jennie Byrne,
Andre Brizard,
Dietger Niederwieser,
Julie Freeman-Edward,
Gavin Cuthbert,
Nick Bown,
Richard E. Clark,
Elizabeth P Nacheva,
Anthony R Green, and
Michael W. N. Deininger
From the Department of Hematology, University of Cambridge, Cambridge, United Kingdom; Department of Hematology, University Hospital, Poitiers, France; Department of Hematology, City Hospital, Nottingham, United Kingdom; Department of Hematology, University Hospital, Leipzig, Germany; Department of Hematology, Royal Liverpool University Hospital, Liverpool, United Kingdom; Cytogenetics Unit, Institute for Human Genetics, University of Newcastle-upon-Tyne, Newcastle-upon-Tyne, United Kingdom; BMT/Leukemia, Oregon Health and Science University, Portland.
Deletions of the derivative chromosome 9 occur in a subset of patients with Philadelphia chromosome–positive chronic myeloid leukemia (CML) and are associated with a poor prognosis on standard drug therapy. However, it is currently unknown if the presence of deletions influences the response to imatinib, an Abl-specific tyrosine kinase inhibitor, that has recently shown excellent hematologic and cytogenetic responses in patients with CML. We, therefore, compared hematologic and cytogenetic responses with imatinib in 397 patients with CML, and survival and progression in 354 of these patients, according to deletion status and disease phase. We found no difference in survival between patients with and without deletions, contrasting with previous reports in cohorts with a lower proportion of patients treated with imatinib. However, the time to disease progression on imatinib treatment was significantly shorter for patients with deletions, both in chronic phase (P = .02) and advanced phases (P = .02). Moreover, both in chronic phase and more advanced phases of CML, hematologic and cytogenetic responses were uniformly lower in patients with deletions, with significant differences seen for hematologic response (P = .04), for major cytogenetic response (P = .008) in chronic phase, and for hematologic response in advanced phases (P = .007) of CML. This finding suggests that differences in survival may become apparent with longer follow-up.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. W. Deininger
Milestones and Monitoring in Patients with CML Treated with Imatinib
Hematology,
January 1, 2008;
2008(1):
419 - 426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kreil, M. Pfirrmann, C. Haferlach, K. Waghorn, A. Chase, R. Hehlmann, A. Reiter, A. Hochhaus, N. C. P. Cross, and for the German Chronic Myelogenous Leukemia (CML)
Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia
Blood,
August 15, 2007;
110(4):
1283 - 1290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Castagnetti, G. Marzocchi, S. Luatti, F. Buontempo, C. Baldazzi, F. Palandri, P. Giannoulia, M. Amabile, I. Iacobucci, M. Mancini, et al.
Deletions of the Derivative Chromosome 9 Do Not Influence Response to Imatinib of Early Chronic Phase Chronic Myeloid Leukemia Patients (A GIMEMA Working Party Analysis).
Blood (ASH Annual Meeting Abstracts),
November 1, 2006;
108(11):
2112 - 2112.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, et al.
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Blood,
September 15, 2006;
108(6):
1809 - 1820.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hughes, M. Deininger, A. Hochhaus, S. Branford, J. Radich, J. Kaeda, M. Baccarani, J. Cortes, N. C. P. Cross, B. J. Druker, et al.
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Blood,
July 1, 2006;
108(1):
28 - 37.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Deininger, E. Buchdunger, and B. J. Druker
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
Blood,
April 1, 2005;
105(7):
2640 - 2653.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Quintas-Cardama, H. Kantarjian, M. Talpaz, S. O'Brien, G. Garcia-Manero, S. Verstovsek, M. B. Rios, K. Hayes, A. Glassman, B. N. Bekele, et al.
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia
Blood,
March 15, 2005;
105(6):
2281 - 2286.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, G. W. Dewald, M. L. Litzow, J. Cortes, M. J. Mauro, M. Talpaz, and H. M. Kantarjian
Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment
Mayo Clin. Proc.,
March 1, 2005;
80(3):
390 - 402.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. O'Brien, A. Tefferi, and P. Valent
Chronic Myelogenous Leukemia and Myeloproliferative Disease
Hematology,
January 1, 2004;
2004(1):
146 - 162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
